ACTD Module 3 Quality Documentation: What Thailand FDA Expects

Why Module 3 Is the Most Critical ACTD Section

The ASEAN Common Technical Dossier (ACTD) is structured in four parts. For most imported generic pharmaceutical products, the Quality documentation — Part II of the ACTD, equivalent to Module 3 in ICH CTD format — is the most extensively reviewed and the most frequent source of deficiency notices from Thailand FDA.

ACTD Part II (Module 3) Structure

3.2.S — Drug Substance (Active Pharmaceutical Ingredient) - Nomenclature, structure, and physicochemical properties - Manufacturing process (synthesis route, controls, impurity profile) - Characterization and control specifications - Stability data

3.2.P — Drug Product (Finished Pharmaceutical Product) - Description and composition - Pharmaceutical development rationale - Manufacturing process and process controls - Controls of finished product (specification and analytical methods) - Container-closure system - Stability data

3.2.A — Appendices - Facilities and equipment - Adventitious agents safety evaluation

Key Quality Issues Thai FDA Scrutinizes

Impurity Limits and Control Thai FDA reviewers pay close attention to impurity specifications. Degradation products identified in stability studies must be justified by ICH Q3B(R2) thresholds and consistent between the drug substance and finished product specifications.

Analytical Method Validation Every analytical method used in the finished product specification must be validated covering specificity, linearity, accuracy, precision, and robustness. Pharmacopoeia methods still require verification data.

Stability Data Quality This is the most frequent deficiency area. Thai FDA requires: - Long-term stability studies under Zone IVb conditions: 40°C / 75% RH - Accelerated stability studies: 40°C / 75% RH for 6 months - Photostability per ICH Q1B - Minimum 12 months long-term data at submission (24 months preferred)

Process Validation Thai FDA expects process validation data for commercial-scale manufacturing.

Common Dossier Preparation Mistakes

• →Stability data shows OOS results at later time points without investigation
• →Analytical methods referenced in specification but not included in the dossier
• →Container-closure system described differently across sections
• →Manufacturing process described at pilot scale without commercial batch data

Summary

Module 3 of the ACTD dossier is where most Thailand FDA drug registration reviews succeed or fail. Manufacturers who maintain audit-ready quality documentation — with Zone IVb stability data, validated analytical methods, and complete manufacturing and validation records — are significantly better positioned for efficient Thailand FDA registration outcomes.